Wide Ranks

ATHE

Alterity Therapeutics Limited

1.09

Top Statistics
Market Cap 10 M Forward PE -547.74 Revenue Growth 38.40 %
Current Ratio 3.54 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -295.67 Enterprise / Revenue 1439.73 Price To Sales Trailing12 Months 2.53
Profitability
Profit Margins 0.00 % Operating Margins -612.91 %
Balance Sheet
Total Cash 12 M Total Cash Per Share 0.0020 Total Debt 159045
Total Debt To Equity 1.15 Current Ratio 3.54 Book Value Per Share 0.0030
All Measures
Short Ratio 30.00 % Message Board Id finmb_2383747 Shares Short Prior Month 6216
Return On Equity -1.04 City Melbourne Uuid 7d2b4277-cadd-3872-afb9-8272c07044dd
Previous Close 1.06 First Trade Date Epoch Utc 1 B Book Value 0.0030
Beta 0.6840 Total Debt 159045 Volume 5751
Price To Book 363.33 Last Split Date 1 B Fifty Two Week Low 1.00
Total Cash Per Share 0.0020 Total Revenue 4 M Shares Short Previous Month Date 1 B
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -612.91 %
Net Income To Common -19123464 Short Percent Of Float 0.0004 Implied Shares Outstanding 9 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 12970
Average Volume10days 12970 Total Cash 12 M Next Fiscal Year End 1 B
Revenue Per Share 0.6000 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.06 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.21 Open 1.08
Free Cashflow -5361769 State VIC Dividend Yield 0.00 %
Return On Assets -0.5266 Time Zone Short Name EST Trailing Eps -1.91
Day Low 1.06 Address1 350 Collins Street Shares Outstanding 8 M
Price Hint 4 Target High Price 0.0000 Website https://alteritytherapeutics.com
52 Week Change -0.3978 Average Volume 11887 Forward Eps -0.0900
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 310.40 %
Last Split Factor 1:10 Regular Market Day High 1.09 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 1.15 Fifty Two Week High 5.41
Day High 1.09 Shares Short 3679 Regular Market Open 1.08
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 1439.73
Revenue Growth 38.40 % Shares Percent Shares Out 0.0004 Operating Cashflow -12605824
Currency USD Time Zone Full Name America/New_York Market Cap 10 M
Is_nasdaq_100 False Zip 3000 Quote Type EQUITY
Industry Biotechnology Long Name Alterity Therapeutics Limited Regular Market Day Low 1.06
Held Percent Institutions 0.0128 Current Price 1.09 Address2 Suite 4 Level 14
Enterprise To Ebitda -295.67 Financial Currency AUD Current Ratio 3.54
Gross Margins 94.67 % Industry Disp Biotechnology Country Australia
Float Shares 3 B Two Hundred Day Average 1.65 Enterprise Value 5 B
Price To Sales Trailing12 Months 2.53 Forward PE -547.74 Regular Market Volume 5751
Ebitda -19571604 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia.

The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease.

It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease.

The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.

Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.